Extended Data Fig. 1: Positioning and sample availability of Leuven RWD cohort.
Positioning of Leuven RWD cohort relative to ICB-treated arms of relevant phase III clinical RCC trials and specific validation cohorts used in this study. Data shown are as per latest report (before August 2023) from the Checkmate025 trial (CM025, nivolumab arm)80, Checkmate214 (CM214, ipilimumab-nivolumab arm)81, Keynote-426 (KN-426, axitinib-pembrolizumab arm)82, Checkmate-9ER (CM9ER, cabozantinib-nivolumab arm)83,84, CLEAR (lenvatinib-pembrolizumab arm)85,86, Javelin101 (avelumab-axitinib arm, PFS and ORR as reported in Motzer et al.20), Immotion150 (atezolizumab±bevacizumab arms; data as reported in CRI iAtlas survival data67), Miao et al. (data as reported in CRI iAtlas survival data), Choueiri et al.38 (data as reported in CRI iAtlas survival data). Colours are indicating the ICB type used in the study, brown represents a mixed cohort of both anti-PD1 and anti-PD1/anti-CTLA4. N numbers represent number of patients. a, Bar chart showing median progression-free survival (mPFS) with 95% confidence interval as error bars. mPFS is indicated above the bar. b, Bar chart showing median overall survival (mOS) with 95% confidence interval as error bars. Cohorts with median OS not reached were omitted (that is, Javelin101, Immotion150). mOS is indicated above the bar. c, Stacked bar chart showing proportion of categories of best response (complete response (CR), partial response (PR), non-responder (NR)). d, Bar chart showing median follow-up time. In case the upper 95% CI value was ‘not reached’, the upper side of the error bar is omitted. e, Flowchart indicating sample availability or loss in the Leuven RWD cohort (created with Biorender.com).
